122 related articles for article (PubMed ID: 37619407)
21. Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study.
Qu Y; Zhao D; Mu J; Che N; Zhang C; Liu Z; Su D; Zhou L; Zhang H; Wei L
Tumour Biol; 2016 Jan; 37(1):887-96. PubMed ID: 26254613
[TBL] [Abstract][Full Text] [Related]
22. A case of invasive mucinous adenocarcinoma of the lung showing stepwise progression at the primary site.
Kawai H; Sugano M; Nakano N; Muratani M; Sakashita S; Goto Y; Noguchi M
Lung Cancer; 2019 Oct; 136():94-97. PubMed ID: 31472337
[TBL] [Abstract][Full Text] [Related]
23. Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma.
Wakejima R; Inamura K; Ninomiya H; Nagano H; Mun M; Okumura S; Okubo K; Ishikawa Y
Pathol Int; 2020 Feb; 70(2):72-83. PubMed ID: 31859434
[TBL] [Abstract][Full Text] [Related]
24. The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation.
Duruisseaux M; Antoine M; Rabbe N; Poulot V; Fleury-Feith J; Vieira T; Lavolé A; Cadranel J; Wislez M
Lung Cancer; 2014 Mar; 83(3):334-40. PubMed ID: 24461303
[TBL] [Abstract][Full Text] [Related]
25. Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma.
Matsukita S; Nomoto M; Kitajima S; Tanaka S; Goto M; Irimura T; Kim YS; Sato E; Yonezawa S
Histopathology; 2003 Jan; 42(1):26-36. PubMed ID: 12493022
[TBL] [Abstract][Full Text] [Related]
26. Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer.
Suda K; Ohara S; Fujino T; Hamada A; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
Clin Lung Cancer; 2022 Jan; 23(1):e60-e68. PubMed ID: 34750065
[TBL] [Abstract][Full Text] [Related]
27. Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma.
Hattori A; Hirayama S; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K
J Thorac Oncol; 2019 Feb; 14(2):265-275. PubMed ID: 30368010
[TBL] [Abstract][Full Text] [Related]
28. Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation.
Cheng B; Deng H; Zhao Y; Xiong J; Liang P; Li C; Liang H; Shi J; Li J; Xiong S; Lai T; Chen Z; Wu J; Qian T; Huan W; Ng MTA; He J; Liang W
Eur Radiol; 2022 Sep; 32(9):5869-5879. PubMed ID: 35348863
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma.
Matsui T; Sakakura N; Koyama S; Nakanishi K; Sasaki E; Kato S; Hosoda W; Murakami Y; Kuroda H; Yatabe Y
Ann Thorac Surg; 2021 Oct; 112(4):1118-1126. PubMed ID: 33242433
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for lymph node metastasis and surgical methods in patients with early-stage peripheral lung adenocarcinoma presenting as ground glass opacity.
Wang Y; Jing L; Wang G
J Cardiothorac Surg; 2020 Aug; 15(1):121. PubMed ID: 32782020
[TBL] [Abstract][Full Text] [Related]
31. Invasive mucinous adenocarcinoma of the lung: Serial CT findings, clinical features, and treatment and survival outcomes.
Beck KS; Sung YE; Lee KY; Han DH
Thorac Cancer; 2020 Dec; 11(12):3463-3472. PubMed ID: 33021074
[TBL] [Abstract][Full Text] [Related]
32. Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity.
Li M; Xi J; Zhang H; Jin X; Zhang J; Feng M; Zhan C; Wang Q
Ann Thorac Cardiovasc Surg; 2022 Oct; 28(5):320-328. PubMed ID: 35644565
[TBL] [Abstract][Full Text] [Related]
33. Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma.
Gao RW; Berry MF; Kunder CA; Khuong AA; Wakelee H; Neal JW; Backhus LM; Shrager JB
J Thorac Cardiovasc Surg; 2017 Dec; 154(6):2092-2099.e2. PubMed ID: 28863952
[TBL] [Abstract][Full Text] [Related]
34. Management of Ground-Glass Opacities in the Lung Cancer Spectrum.
Zhang Y; Fu F; Chen H
Ann Thorac Surg; 2020 Dec; 110(6):1796-1804. PubMed ID: 32525031
[TBL] [Abstract][Full Text] [Related]
35. Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas.
Lee HY; Cha MJ; Lee KS; Lee HY; Kwon OJ; Choi JY; Kim HK; Choi YS; Kim J; Shim YM
J Thorac Oncol; 2016 Jul; 11(7):1064-73. PubMed ID: 27016260
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS).
Buyuk M; Ozluk Y; Bakkaloglu DV; Ozkan B; Firat P; Yilmazbayhan D
Turk Patoloji Derg; 2023; 39(1):64-74. PubMed ID: 36367122
[TBL] [Abstract][Full Text] [Related]
37. MUC6 expression is a preferable prognostic marker for invasive mucinous adenocarcinoma of the lung.
Yamanoi K; Fujii C; Yuzuriha H; Kumazawa M; Shimoda M; Emoto K; Asamura H; Nakayama J
Histochem Cell Biol; 2022 Jun; 157(6):671-684. PubMed ID: 35353213
[TBL] [Abstract][Full Text] [Related]
38. Postoperative survival of pulmonary invasive mucinous adenocarcinoma versus non-mucinous invasive adenocarcinoma.
Cui D; Xie S; Liu Q
BMC Pulm Med; 2023 Jan; 23(1):9. PubMed ID: 36624430
[TBL] [Abstract][Full Text] [Related]
39. Clinical course of stage IV invasive mucinous adenocarcinoma of the lung.
Cha YJ; Kim HR; Lee HJ; Cho BC; Shim HS
Lung Cancer; 2016 Dec; 102():82-88. PubMed ID: 27987593
[TBL] [Abstract][Full Text] [Related]
40. Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity.
Yoshida Y; Kokubu A; Suzuki K; Kuribayashi H; Tsuta K; Matsuno Y; Kusumoto M; Kanai Y; Asamura H; Hirohashi S; Shibata T
Jpn J Clin Oncol; 2007 Dec; 37(12):907-12. PubMed ID: 18089646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
